University of Miami Thinking Through Alzheimer’s Exploring Cognition, Psychopharmacology and Geriatric Psychiatry 2026

University of Miami Thinking Through Alzheimer’s Exploring Cognition, Psychopharmacology and Geriatric Psychiatry 2026

1. Overview

The University of Miami Thinking Through Alzheimer’s Exploring Cognition, Psychopharmacology and Geriatric Psychiatry 2026 course provides a comprehensive clinical update on dementia care and geriatric mental health. The program covers the spectrum from normal cognitive aging to early Alzheimer’s diagnosis, highlighting new breakthroughs in neuropsychological assessments, emerging biomarkers, and the latest pharmacological and non-pharmacological management strategies.

Course Date: February 23-27, 2026 | Monday-Friday | 9:00am to 12:15pm

• Anxiety, depression and other mental health condition in later life can reduce longevity, increase the risk of medical and cognitive disorders and lead to poorer outcomes. Most concerning is the fact that the prevalence of cognitive disorders is increasing rapidly as people live longer. Reducing the risk of cognitive disorders such as Alzheimer’s Disease and Related Dementias (ADRD) is as essential to the clinician as reducing hypertension and diabetes in reducing cardiovascular disease.
• This seminar is designed to educate the practitioners and equip them with essential knowledge and state-of-the-art scientific methods to diagnose Alzheimer’s Disease and Related Dementias (ADRD) at its earliest stages and assist patients and their loved ones. Understanding normal cognitive neurology and stradegies to reduce the risk of developing Alzheimer’s disease will also be discussed. Drawing on the presenters’ vast scientific and clinical expertise, the participants will be able to differentiate different cognitive syndromes and the etiological underpinnings of various clinical presentations. In addition, the participant will be familiarized with state-of-the-art neuropsychological and novel neuroimaging and plasma-based biomarkers methods to detect the earliest stages of Alzheimer’s Disease.
• This presentation will also provide a comprehensive review of essential geriatric psychopharmacology in the treatment of the most common psychiatric and mental health conditions as well as the latest in emerging pharmacological agents in the treatment and management of Alzheimer’s Disease and its comorbid psychiatric and behavioral manifestations.

2. Learning Objectives

Upon completion of this activity, participants will be able to:

• Describe the promotion of brain health and longevity through evidence-based prevention.
• Differentiate between normal cognitive neurology, mild cognitive impairment (MCI), and clinical dementia.
• Demonstrate how to identify the underlying brain disorders causing clinical cognitive impairment in older adults.
• Identify the evidence-based, emerging brain biomarkers in cognitive disorders that help to diagnose at-risk older individuals for Alzheimer’s Disease and Related Dementias (ADRD).
• Identify the role of traditional and novel cognitive neuropsychological testing in early diagnosis of cognitive disorders in older individuals.
• Differentiate Alzheimer’s Disease from non- Alzheimer’s Disease pathology
• Describe current pharmacological and nonpharmacological approaches to the treatment of Alzheimer’s Disease and Related Dementias (ADRD).
• Identify the emerging and promising agents in the treatment and management of early Alzheimer’s disease (AD).
• Recognize geriatric psychopharmacology and how to optimally treat the more challenging geriatric mental health conditions.

3. Target Audience

Best for psychiatrists and neurologists who want updates on Alzheimer’s biomarkers, cognitive assessments, and geriatric psychopharmacology.

4. Topics

1. 01 Normal Cognitive Aging with Philip Harvey, PhD

2. 02 Delaying or Preventing Alzheimer’s Evidence-Based Risk Reduction With Kirsten CrenshaW, PsyD

3. 03 Clinical Overview of Common Neurodegenerative Disorders in Older Adults With Alexandra Ortega, PsyD

4. 04 New Breakthroughs in cognitive Neuropsychological Assessment With David Loewenstein, PhD

5. 05 Guiding Practitioners in Identifying Individuals Who Are Most at Risk for Amnestic MCI with Rosie Curiel-Cid, PsyD

6. 06 Emerging Biomarkers in Diagnosing Early Alzheimer’s Disease with Rosie Curiel-Cid, PsyD

7. 07 Treating the Family Constellation in Geriatric Psychiatry and Dementia with Elizabeth Crocco, MD

8. 08 The Most Common Treatment Challenges in Geriatric Psychopharmacology with Elizabeth Crocco, MD

9. 09 Pharmacological and Non-Pharmacological Management of Alzheimer’s and Related Dementias with Elizabeth Crocco, MD

10. 10 The New Emerging Pharmacological Agents for Alzheimer’s Disease with Elizabeth Crocco, MD